Evidence map›Paper›PMID 41145941›Full record

ArticleAnnals of surgical oncology2026

Large Resectable Pancreatic Cancer is Associated with Futile Surgery: A Resectable But Not Curable Disease?

Sho Kiritani, Yoshikuni Kawaguchi, Yusuke Kazami, Satoru Abe, Yujiro Nishioka, Yuichiro Mihara, Akihiko Ichida, Takeshi Takamoto, Nobuhisa Akamatsu, Kiyoshi Hasegawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sho KiritaniHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yoshikuni KawaguchiHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yusuke KazamiHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Satoru AbeHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yujiro NishiokaHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yuichiro MiharaHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Akihiko IchidaHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takeshi TakamotoHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nobuhisa AkamatsuHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kiyoshi HasegawaHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hasegawa-2su@h.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0001-8734-740X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA subset of patients with resectable pancreatic cancer (PC) experience early recurrence after curative-intent pancreatectomy and subsequently face a poor prognosis. However, the underlying factors associated with such a futility of surgery remain unclear.

methodsThis retrospective cohort study analyzed 369 patients with resectable PC who underwent curative pancreatectomy between 2008 and 2022. Futile surgery was defined as recurrence within 8 months postoperatively. Receiver operating characteristic curve and Youden's index distribution were used to identify the optimal tumor diameter cutoff, which then was applied to survival analysis.

resultsA diameter of 3 cm corresponded to the peak of Youden's index and was adopted as the cutoff value. Patients were classifed into the large group (≥ 3 cm; n = 206) and small group (< 3 cm; n = 163). The median overall survival (OS) was significantly shorter in the large group (2.3 years) than in the small group (7.6 years) (p < 0.01). The large group with neoadjuvant therapy had a median OS of 3.4 years, comparable with 2.3 years for the large group with upfront surgery (p = 0.33). Multivariable analysis identified the large group as a poor independent prognostic factor (hazard ratio, 2.2; p < 0.01). Even after R0 resection, local recurrence was more frequently observed in the large group (34.1% vs 11.8%; p < 0.01).

conclusionsA tumor size of 3 cm was associated with surgical futility in resectable pancreatic cancer and served as a useful factor for fine stratification of long-term postoperative outcomes.

Indexed as

Medical FutilityNeoplasm Recurrence, LocalPancreatectomyPancreatic NeoplasmsAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoadjuvant TherapyPrognosisRetrospective StudiesSurvival RateFutile surgeryLocal recurrencePancreatectomyResectable pancreatic cancerTumor diameter

Identifiers

PMID41145941
PMCPMC12765747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.